Unravelling the relevance of CLEC12A as a cancer stem cell marker in myelodysplastic syndrome

Abstract excerpt

Summary Evidence of distinct disease propagating stem cells in myelodysplastic syndrome ( MDS ) has emerged in recent years. However, immunophenotypic characterization of these cancer stem cells remains sparse. In acute myeloid leukaemia ( AML ), we have previously described aberrant expression of the C‐type lectin domain family 12, member A ( CLEC 12A) as a stable and reliable marker of leukaemia blasts and as a...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Acute Myeloid Leukemia Research
• Share to Myeloproliferative Neoplasms: Diagnosis and Treatment
• Share to Sarcoma Diagnosis and Treatment